Clinical trials: Primary Hypertension
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)
Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- CONFORTK (NCT03257813)
- Testing
- PRO-122, Krytantek Ofteno®
- Volunteers
- 60 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Cardiovascular Disease, Hypertension
Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease
Cardiovascular is a major cause of mortality in Iran, accounting for 45.7% of deaths. In Golestan (North Eastern Iran) preliminary findings from follow-up of the Golestan Cohort are consistent with national figures: with 45% (at…
- Conditions
- Cardiovascular Disease, Hypertension, Hyperlipidemia, Heart Disease
- Trial name
- Polypill (NCT00603590)
- Testing
- Polypill
- Where
- Iran
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Diabetes Mellitus, Type 2, Hypertension
The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care
This project tests a model of chronic disease medication management in which the decision to initiate or adjust medical therapy is directly linked to a sequence of subsequent clinical actions (e.g.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
- Trial name
- NCT01586897
- Testing
- Medication Metronome, Usual Care
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital
Hypertension
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E).
- Trial name
- NCT01302691
- Testing
- losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E), Losartan potassium, Amlodipine besylate
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure
Sleep apnea is characterized by repetitive episodes of decreased or interrupted airflow in the upper airways during sleep. Obstructive sleep apnea syndrome (OSAS) is the most common sleep-related breathing disorder and is…
- Trial name
- NCT01560975
- Testing
- SENSIMED Triggerfish®
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sensimed AG
Hypertension, Portal
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this…
- Trial name
- NCT05161481
- Testing
- Avenciguat (BI 685509)
- Where
- 45 sites in United States, Argentina and 20 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Orthostatic Hypertension
Intravenous Norepinephrine for Orthostatic Hypotension
Background: Orthostatic hypotension is a fall in blood pressure when standing up. Normally, a reflex action of the automatic nervous system makes blood vessels tighten when people stand up.
- Trial name
- NCT01285908
- Testing
- Intravenous Norepinephrine Infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glaucoma; Drugs, Normal Tension Glaucoma
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
This study evaluates the possible acute changes in peripapillary blood flow after instillation of antiglaucoma medications in patients with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), or ocular hypertension…
- Conditions
- Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
- Trial name
- NCT03323164
- Testing
- Timolol Maleate, Brimonidine Tartrate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Wills Eye
Hypertension
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
The purpose of this study is to evaluate the effects on blood pressure control, pulse wave velocity, as well as safety and tolerability of felodipine single or combine with other drugs in Chinese Hypertension patients.
- Trial name
- NCT02336607
- Testing
- Felodipine tablet (Plendil) alone, Felodipine tablet (Plendil)+Hydrochlorothiazide, Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
- Volunteers
- 529 people
- Sponsor
- AstraZeneca
Essential Hypertension
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
- Trial name
- NCT00430950
- Testing
- olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg
- Where
- 41 sites in Belgium, Germany and 2 more
- Volunteers
- 1,011 people
- Sponsor
- Daiichi Sankyo
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Hypertension
Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid…
- Trial name
- NCT01368185
- Volunteers
- 1,705 people
- Sponsor
- Organon and Co
Chronic Kidney Diseases, Hypertension
Chronic Kidney Disease Clinical Decision Support
To prevent serious chronic kidney disease (CKD) complications such as end-stage renal disease and cardiovascular events, better strategies are needed to identify, treat, and refer CKD patients seen in primary care clinics.
- Conditions
- Chronic Kidney Diseases, Hypertension, Diabetes
- Trial name
- CKD-CDS (NCT03890588)
- Testing
- CKD enhanced clinical decision support
- Where
- United States
- Volunteers
- 6,295 people
- Sponsor
- HealthPartners Institute
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
- Trial name
- NCT03896633
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 637 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Hypertension
Trial of Low and High Intensity Strategies to Maintain BP Control
The long-range goal of this research is to advance understanding of long-term blood pressure (BP) control in patients with uncontrolled hypertension (HTN).
- Trial name
- NCT00760552
- Testing
- High Intensity Intervention, Low Intensity Intervention, All- 6 month pharmacist intervention
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- US Department of Veterans Affairs
Essential Hypertension
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.
- Trial name
- NCT00857285
- Testing
- olmesartan medoxomil, losartan potassium
- Where
- 3 sites in Taiwan
- Volunteers
- 130 people
- Sponsor
- Daiichi Sankyo
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.
- Conditions
- Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
- Trial name
- ESRA (NCT05339087)
- Testing
- Riociguat Oral Tablet
- Where
- 8 sites in Austria, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo